OR WAIT 15 SECS
A collaboration has been agreed between AB SCIEX and Alturas Analytics to accelerate the adoption of dried blood spot analysis for drug discovery and development.
A collaboration has been agreed between AB SCIEX and Alturas Analytics to accelerate the adoption of dried blood spot analysis for drug discovery and development. This analysis is designed to help pharmaceutical companies by simplifying the collection, storage and shipment of samples for pre-clinical and clinical studies in the drug development process. Scientists at Alturas are using QTRAP 5500 technology from AB SCIEX and micro-flow chromatography technology from Eksigent to further develop novel workflows based on microflow LC–MS for dried blood spot analysis and validate them to ensure that they meet Alturas’ quality assurance requirements. The new workflows are designed to require smaller sample volumes and provide sensitivity and low coefficient of variations.
“Dried blood spot analysis is a technique that can be used to solve complex bioanalytical problems,” said Shane Needham, laboratory director, Alturas Analytics. “Recent gains in sensitivity in analytical instrumentation have opened up remarkable new possibilities for pharmaceutical companies to take advantage of dried blood spot analysis.” Needham says that through their LC–MS instrumentation “AB SCIEX and Eksigent have helped to change the way we look at this type of analysis.“